Trial reportEye (London, England)2026
Long term evolutions of hard exudates after anti-VEGF therapy for diabetic macular oedema.
Trial report in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hard Exudates in Diabetic Macular Edema: Automated OCT Quantification and Longitudinal Response to Faricimab.Ophthalmology science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate longitudinal change in hard exudate (HEs) volume over 5-years following anti-VEGF treatment for diabetic macular oedema (DMO).
methodsThis study was a post-hoc analysis of structural optical coherence tomography (OCT) volume scans collected in the Diabetic Retinopathy Clinical Research Network Protocol T extension trial. A deep learning model was used to segment HEs and compute a HEs volume (mm³) for the entire OCT scan at baseline, 12, 24, 52, 104, 260 weeks (w). HEs volume was also quantified within the central subfield (CSF), inner ring (IR), and outer ring (OR) of ETDRS grid. Change in HEs over time was compared among treatment arms and a multiple regression analysis was used to evaluate the impact of HEs on visual outcomes relative to other biomarkers.
results116 eyes were included (aflibercept: 44, bevacizumab: 30, ranibizumab: 42) in the final analysis. Across all studied regions, HEs significantly decreased through w52 (p < 0.001), and from w52 to w104, a further significant decrease was observed in the total macula and IR, though no additional reduction between w104 and w260. Change in VA at w260 was associated with baseline VA and w260 change in CST, but not with baseline HEs. At w52, HEs reduction was significantly greater with aflibercept and ranibizumab compared to bevacizumab, but no longer significant at w104 and w260.
conclusionsFollowing anti-VEGF therapy, HEs decreased through w104, but stabilised after that, and initial differences among agents disappeared by two years. The change in HEs did not predict w260 visual outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.